Answers are grounded in this paper and cite their sources.
Active vaccine safety surveillance, which involves directly engaging with vaccine recipients to actively solicit information on adverse events following immunization, complements spontaneous reporting systems. This commentary provides a comparative overview of three national active vaccine safety surveillance systems: AusVaxSafety (Australia), CANVAS (Canada) and V-safe (United States) across six key surveillance system evaluation attributes. Each system played an essential role during the COVID-19 pandemic and continues to contribute to global post-marketing vaccine safety surveillance. Each has various strengths and limitations. AusVaxSafety, established in 2014, is well integrated with routine healthcare settings for opt-out surveillance and offers frequent public reporting. CANVAS, established in 2009, offers a unique cohort-based design with inclusion of control groups. V-safe, established in 2020, has proven scalability and broad population reach due to its accessible web-based design. The various features of each system offer insights to inform future vaccine safety surveillance efforts.
No takes yet. Share an insight, caveat, or question.
Carter et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: